<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Endothelial glycocalyx perturbation contributes to <z:mp ids='MP_0003070'>increased vascular permeability</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study we set out to evaluate whether: (1) glycocalyx is perturbed in individuals with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and (2) oral glycocalyx precursor treatment improves glycocalyx properties </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Male participants with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 10) and controls (n = 10) were evaluated before and after 2 months of sulodexide administration (200 mg/day) </plain></SENT>
<SENT sid="3" pm="."><plain>The glycocalyx dimension was estimated in two different vascular beds using sidestream dark field imaging and combined <z:chebi fb="0" ids="31624">fluorescein</z:chebi>/<z:chebi fb="0" ids="31696">indocyanine green</z:chebi> angiography for sublingual and <z:chebi fb="46" ids="15035">retinal</z:chebi> vessels, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Transcapillary escape rate of albumin (TER(alb)) and hyaluronan catabolism were assessed as measures of vascular permeability </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Both sublingual dimensions (0.64 [0.57-0.75] μm vs 0.78 [0.71-0.85] μm, p &lt; 0.05, medians [interquartile range]) and <z:chebi fb="46" ids="15035">retinal</z:chebi> glycocalyx dimensions (5.38 [4.88-6.59] μm vs 8.89 [4.74-11.84] μm, p &lt; 0.05) were reduced in the type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> group compared with the controls whereas TER(alb) was increased (5.6 ± 2.3% vs 3.7 ± 1.7% in the controls, p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>In line with these findings, markers of hyaluronan catabolism were increased with <z:mp ids='MP_0002055'>diabetes</z:mp> (hyaluronan 137 ± 29 vs 81 ± 8 ng/ml and hyaluronidase 78 ± 4 vs 67 ± 2 U/ml, both p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Sulodexide increased both the sublingual and <z:chebi fb="46" ids="15035">retinal</z:chebi> glycocalyx dimensions in participants with <z:mp ids='MP_0002055'>diabetes</z:mp> (to 0.93 [0.83-0.99] μm and to 5.88 [5.33-6.26] μm, respectively, p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>In line, a trend towards TER(alb) normalisation (to 4.0 ± 2.3%) and decreases in plasma hyaluronidase (to 72 ± 2 U/ml, p &lt; 0.05) were observed in the <z:mp ids='MP_0002055'>diabetes</z:mp> group </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION/INTERPRETATION: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with glycocalyx perturbation and <z:mp ids='MP_0003070'>increased vascular permeability</z:mp>, which are partially restored following sulodexide administration </plain></SENT>
<SENT sid="10" pm="."><plain>Further studies are warranted to determine whether long-term treatment with sulodexide has a beneficial effect on cardiovascular risk </plain></SENT>
<SENT sid="11" pm="."><plain>TRIAL REGISTRATION: www.trialregister.nl NTR780/ http://isrctn.org ISRCTN82695186 FUNDING: An unrestricted Novartis Foundation for Cardiovascular Excellence grant (2006) to M </plain></SENT>
<SENT sid="12" pm="."><plain>Nieuwdorp/E </plain></SENT>
<SENT sid="13" pm="."><plain>S </plain></SENT>
<SENT sid="14" pm="."><plain>G </plain></SENT>
<SENT sid="15" pm="."><plain>Stroes, Dutch Heart Foundation (grant number 2005T037) </plain></SENT>
</text></document>